Howard Silverboard, MD
Pulmonary Disease · Atlanta, GANPI 1285609453
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.5% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 30.5% of the total.
Across 190 payments — averaging $24.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$726
- Insmed, Inc.$371
- Amgen$263
- Actelion Pharmaceuticals US, Inc.$166
- Sanofi$163
- plus $2K from 27 others
Across 8 payments — averaging $5932.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$45K
- Novartis$2K
What the payments were for
- Travel & lodging$3547%
- Food & beverage$4,37993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $1,444 |
| GSK | 44 | $726 |
| Insmed, Inc. | 13 | $371 |
| Amgen(2 entities) | 12 | $263 |
| Actelion Pharmaceuticals US, Inc. | 7 | $166 |
| Sanofi | 5 | $163 |
| Boehringer Ingelheim | 8 | $159 |
| Regeneron Healthcare Solutions, Inc. | 7 | $152 |
| Grifols USA, LLC | 6 | $151 |
| Merck | 6 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $88 |
| Mylan Specialty L.p. | 4 | $80 |
| Johnson & Johnson(2 entities) | 3 | $78 |
| Philips North America LLC | 4 | $76 |
| Electromed, Inc. | 5 | $71 |
| Baxter Healthcare | 3 | $69 |
| United Therapeutics Corporation | 3 | $69 |
| Verona Pharma, Inc. | 3 | $65 |
| AbbVie | 3 | $55 |
| Veran Medical Technologies, Inc. | 2 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Inogen, Inc. | 2 | $32 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $24 |
| Shire North American Group Inc | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Gilead | 1 | $15 |
| CMP Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,733 in reported general payments places this provider in the 55th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 197 | $154,095 |
| OfevNintedanib Esylate | 11 | $140,103 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $23,578 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $18,415 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $7,293 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $3,062 |
| Arnuity ElliptaFluticasone Furoate | 11 | $2,284 |
| Wixela InhubFluticasone Propion/Salmeterol | 22 | $1,367 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,205 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $780 |
| Montelukast Sodium | 34 | $273 |
| Prednisone | 36 | $225 |
| Azithromycin | 23 | $167 |
| Azelastine Hcl | 11 | $164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $726 | $198,372292 claims |
| Boehringer IngelheimOfev | $159 | $140,10311 claims |
| AstraZenecaSymbicort | $1,444 | $7,29316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.